Program:
Start Year:
2023
Why did you choose Duke for your residency training?
The opportunities for research, for advocacy, for working with the amazing faculty that are such movers and shakers in the field and for learning with and serving a diverse patient population felt unparalleled. But ultimately, I chose Duke because of the residents.
What excites you about the residency program at Duke Ob/Gyn?
The thing that stood out to me the most about Duke was the culture created among the residents, and I feel so lucky to get to train somewhere where everyone is so excited to help everyone else succeed.
What are your career goals?
I really enjoy participating in goals of care conversations, and I like the OR. Right now I am interested in learning more about how gyn onc merges those two areas, but I am excited to get to try out so many of the different aspects of ob/gyn here! I also enjoy mentoring, and I love research — so I imagine I will stay in academic medicine regardless of what field I end up in.
Describe your research interests/goals:
I am particularly interested in oncology research, and especially translational research — investigating how and why cancer cells respond to different drugs and figuring out how to use that knowledge to provide our patients the best treatment options that we can.
What are your hobbies?
I love to paint and do anything artsy. I’m a big coffee/tea fan and reader, so I am often coffee shop hopping with a good book.
Education & Training
Undergraduate school & graduation year:
Harvard University, 2018
Medical school & graduation year:
Harvard Medical School, 2023
Publications
Markert T, Courtepatte A, Farah S, Miranne JM. Number of patients with interstitial cystitis/bladder pain syndrome seen before versus during the COVID-19 pandemic at an academic, urban, multisite urogynecology practice. Low Urin Tract Symptoms. 2023 Sep 12. doi: 10.1111/luts.12502. Epub ahead of print. PMID: 37700527.
Prakash J, Markert T, Bain PA, Stoklosa H. Maternal Health Concerns for Pregnant Labor-Trafficked People: A Scoping Review. J Immigr Minor Health. 2023 Aug;25(4):899-905. Epub 2023 Mar 15. PMID: 36920583. Markert T, Kolin DL, Konstantinopoulos PA. Uterine carcinosarcoma associated with a germline nibrin (NBN) mutation. Gynecol Oncol Rep. 2022 Apr 6;40:100979.
Tagde A,* Markert T,* Rajab H, Hirkai M, Alam M, Bouillez A, & Kufe D (2017). Targeting MUC1-C Suppresses Polycomb Repressive Complex 1 in Multiple Myeloma. Oncotarget. 10;8(41):69237-69249. *Co-first author
Hiraki M, Maeda T, Bouillez A, Alam M, Tagde A, Hinohara K, Suzuki Y, Markert T, Miyo M, Komura K, Ahmad R, Rajab H, Kufe D (Nov 2016). MUC1-C activates BMI1 in human cancer cells. Oncogene. 18;36(20):2791-2801.
Oliva, CR, Markert T, Ross Li, White EL, Rasmussen L, Zhang W, Everts M, Moellering DR, Bailey SM, Suto MJ, & Griguer CE. (2016). Identification of Small Molecule Inhibitors of Human Cytochrome c Oxidase that Target Chemoresistant Glioma Cells. J Biol Chem. 291(46):24188-24199
Oliva CR, Markert T, Gillespie GY, & Griguer CE. (2015). Nuclear-encoded cytochrome c oxidase subunit 4 regulates BMI1 expression and determines proliferative capacity of high-grade gliomas. Oncotarget. 6(6):4330-44.
Presentations
Zachary Walker (Presenter), Tahireh Markert, Isa Berzansky, Andrea Lanes, Serene S. Srouji (March 2023). Social Media’s Impact on a Patient’s Choice of Reproductive Endocrinology and Infertility Provider or Clinic – A Survey Based Study. 71st Annual Meeting of the Pacific Coast Reproductive Society, Indiana Wells CA.
Parisa N. Fallah, Gia Ciccolo, Tara Markert, Andrea Pelletier, Victoria Wang, Kevin M. Elias, Sarah Feldman, Stephanie J. Alimena (June 2023). Assessing Disparities in Delays to Ovarian Cancer Care Across the Healthcare System. New England Association of Gynecologic Oncologists, Portland ME.
Zachary Walker MD (Presenter); Tahireh Markert BA; Isa Berzansky BA; Andrea Lanes PhD; Serene S. Srouji MD (March 2023). Social Media’s Impact on a Patient’s Choice of Healthcare Provider – A Survey Based Study. PCRS, Indian Wells CA.
Laura Wollborn (Presenter), James W. Webber, Sudhanshu Mishra, Marta Williams; Chad B. Sussman; Joyce Wang,Tahireh Markert, Cameron E. Comrie, Daniel G. Packard, Monica K. Moore, Julia Spiegel, Stephanie Alimena, Kevin M. Elias (Dec 2022). The impact of ovarian cancer risk factors on miRNA serum profiles in women without ovarian cancer. AACR-JCA, Hawaii.
Tahireh Markert; Alexa Courtepatte; Subrina Farah; Jeannine M. Miranne MD, MS (Nov 2022). Incidence of Interstitial Cystitis/Bladder Pain Syndrome Before the COVID-19 Pandemic versus During the COVID-19 Pandemic. Discover Brigham, Brigham and Women’s Hospital.
Tahireh Markert, Shrabasti Roychoudhury, Dipanjan Chowdhury (Mar 2022). BRCA Dependent Response to ATR Inhibitors. Soma Weiss Student Research Day, Harvard Medical School.
Tara Markert, Nathaniel H. Reeve, Claudia R. Oliva, Ph.D. and Corinne E. Griguer, Ph.D. (2013). Chemoresistance is regulated by the expression of the Nuclear-encoded Cytochrome c Oxidase subunit 4, isoform 1. UAB Comprehensive Cancer Center Annual Retreat, Birmingham, Alabama .
Nathaniel H. Reeve (Presenter), Tara Markert, Claudia R. Oliva, Ph.D. and Corinne E. Griguer, Ph.D. (2013). Cytochrome c Oxidase in Malignant Glioma. UAB Undergraduate Research Exposition, Birmingham, Alabama.
Claudia R. Oliva (Presenter), Ph.D., Corinne E. Grigeur, Ph.D., and Tara Markert. (2013). Cytochrome c Oxidase in Malignant Glioma. Gordon Research Conference.